Select Your Location:
Global
France
Italy

Zanubrutinib in Relapsed/Refractory Follicular Lymphoma

Content Type: Reading

ROSEWOOD (NCT03332017) is a global Phase 2, randomized study designed to assess the efficacy and safety of zanubrutinib + obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 lines of therapy.

Reading
23 May 2025

BGB-3111-215 (NCT04116437) is a Phase 2 study evaluating the safety of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Reading
23 May 2025

Reading
23 May 2025

Reading
23 May 2025